VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection)* to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia. These four countries were selected because they have not only the required facilities and well trained scientific and technical personnel with the experience necessary for running this Phase III study, but also because they have a high incidence of head and neck cancer. CEL-SCI’s partner, Teva Pharmaceuticals Industries, who has the marketing rights to Croatia has selected 2-3 clinical centers in Croatia that have the capability and interest in conducting this study. The Multikine Phase III study is currently being run in 8 countries, including the US, on 3 continents.
